The median overall survival after long-term follow-up (minimum 42 months) in MTC harboring RET M918T on cabozantinib was 44.3 vs 18.9 months for those on placebo (HR, 0.60; 95% CI, 0.38–0.94) (Schlumberger et al. 2017). Here, RET is linked to medullary thyroid gland carcinoma.